Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 29,083 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dose level 1 Clear all
Completed Phase 1 Interventional

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

NCT04155645
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD8233 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Chula Vista, California • Glendale, California • La Mesa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Nov 9, 2026, 5:48 PM EST
Completed Phase 3 Interventional Results available

Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)

NCT01791972
View directory record Official record
Conditions
Exercise-Induced Bronchoconstriction (EIB)
Interventions
Albuterol Spiromax, Placebo Spiromax
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
6
States / cities
San Diego, California • Denver, Colorado • Wheaton, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Nov 9, 2026, 5:48 PM EST
Completed Phase 3 Interventional Results available

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

NCT02584257
View directory record Official record
Conditions
Mild Persistent Asthma
Interventions
methacholine chloride, placebo ProAir HFA, ProAir HFA, Lupin albuterol HFA MDI, placebo Lupin albuterol HFA MDI
Other · Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
17
States / cities
Huntington Beach, California • Mission Viejo, California • Rolling Hills Estates, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Nov 9, 2026, 5:48 PM EST
Terminated Phase 2 Interventional

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

NCT02294357
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Prednisone, Methylprednisolone, Lenalidomide, Pomalidomide
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Encinitas, California • West Hills, California • West Hollywood, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Nov 9, 2026, 5:48 PM EST
Completed Phase 1 Interventional

Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

NCT01186601
View directory record Official record
Conditions
Neoplasms
Interventions
PET tracer (BAY94-9392)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Nov 9, 2026, 5:48 PM EST
Completed Phase 2 Interventional Results available

Immune Disorder HSCT Protocol

NCT01821781
View directory record Official record
Conditions
Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Hyper-IgM, DiGeorge Syndrome, Chediak-Higashi Syndrome, Common Variable Immune Deficiency, Immune Dysregulatory Disorders, Hemophagocytic Lymphohistiocytosis, IPEX, Autoimmune Lymphoproliferative Syndrome, X-linked Lymphoproliferative Syndrome
Interventions
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 9, 2026, 5:48 PM EST
Not yet recruiting Phase 1 Interventional

A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT07906665
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
NI112, Placebo
Drug
Lead sponsor
Sachi Bioworks Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 9, 2026, 5:48 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

NCT05203965
View directory record Official record
Conditions
Familial Alcoholism Vulnerability
Interventions
Mavoglurant (AFQ056), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 9, 2026, 5:48 PM EST
Recruiting Phase 1 Interventional

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697
View directory record Official record
Conditions
Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms, Colonic Neoplasms
Interventions
cyclophosphamide, fludarabine, TNhYP218 CAR T Cells, mesothelin expression testing
Drug · Biological · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 9, 2026, 5:48 PM EST
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110
View directory record Official record
Conditions
Healthy Volunteers, Pulmonary Arterial Hypertension
Interventions
LTP, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
19
States / cities
Scottsdale, Arizona • Orange, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 9, 2026, 5:48 PM EST
Terminated Phase 2 Interventional Results available

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

NCT03785210
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, Liver Metastasis
Interventions
nivolumab, tadalafil, oral vancomycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Nov 9, 2026, 5:48 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Rheumatoid Arthritis Study in Healthy Volunteers

NCT00539760
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK1827771, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Evansville, Indiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Nov 9, 2026, 5:48 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer

NCT04403620
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Intensity-modulated Radiation Therapy (IMRT)
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 9, 2026, 5:48 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184

NCT01824446
View directory record Official record
Conditions
Healthy
Interventions
Radiolabeled SPD602 (FBS0701, SSP-004184)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Nov 9, 2026, 5:48 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

NCT04818346
View directory record Official record
Conditions
NonSegmental Vitiligo
Interventions
INCB054707, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Hoover, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Nov 9, 2026, 5:48 PM EST
Completed Phase 4 Interventional Results available

Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery

NCT01901588
View directory record Official record
Conditions
Strabismus, Delirium on Emergence, Pediatric Disorders
Interventions
Dexmedetomidine, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 7 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Nov 9, 2026, 5:48 PM EST
Completed Phase 1 Interventional

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00089362
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Gastric Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Melanoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Ovarian Epithelial Cancer, Recurrent Prostate Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Basal Cell Carcinoma of the Lip, Stage III Colon Cancer, Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage III Gastric Cancer, Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Lymphoepithelioma of the Oropharynx, Stage III Melanoma, Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Ovarian Epithelial Cancer, Stage III Renal Cell Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Gastric Cancer, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Melanoma, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Ovarian Epithelial Cancer, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Unspecified Adult Solid Tumor, Protocol Specific, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Nov 9, 2026, 5:48 PM EST
Completed Phase 3 Interventional Results available

Phase III Cat-PAD Study

NCT01620762
View directory record Official record
Conditions
Rhinoconjunctivitis
Interventions
Cat-PAD, Placebo
Drug
Lead sponsor
Circassia Limited
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
52
States / cities
Rolling Hills Estates, California • Colorado Springs, Colorado • Denver, Colorado + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Nov 9, 2026, 5:48 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

NCT04253262
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Rucaparib, Copanlisib
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
San Francisco, California • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Nov 9, 2026, 5:48 PM EST
Withdrawn Phase 4 Interventional

Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium

NCT02118688
View directory record Official record
Conditions
Delirium, Agitation
Interventions
Risperidone, Trazodone, Placebo
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Nov 9, 2026, 5:48 PM EST
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation

NCT01895127
View directory record Official record
Conditions
Antibody-mediated Rejection, Humoral Rejection
Interventions
Eculizumab, Immunoglobulin, Plasmapheresis
Drug · Biological · Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Nov 9, 2026, 5:48 PM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults

NCT03045861
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK2838232, Cobicistat
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Nov 9, 2026, 5:48 PM EST
Completed Not applicable Interventional Results available

Hemostasis in Open Acetabulum and Pelvic Ring Surgery Using Tranexamic Acid

NCT02051686
View directory record Official record
Conditions
Acetabulum Fractures
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Nov 9, 2026, 5:48 PM EST
Completed Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma

NCT00003470
View directory record Official record
Conditions
Anaplastic Astrocytoma
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Nov 9, 2026, 5:48 PM EST